share_log

復星醫藥：海外監管公告 - 2023年度募集資金存放與實際使用情況的專項報告

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Mar 26 08:53
Summary by Moomoo AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年3月26日發布了2023年度募集資金存放與實際使用情況的專項報告。報告顯示，復星醫藥於2022年7月非公開發行股票，募集資金總額達人民幣448.38億元，扣除發行費用後淨額為人民幣445.62億元。截至2023年12月31日，已累計使用募集資金人民幣367.14億元。報告期內實際使用了人民幣64.42億元，募集資金餘額為人民幣78.48億元。此外，復星醫藥調整了部分募集資金的投資項目，以加快創新藥物研發進度，並提高資金使用效率。安永華明會計師事務所對募集資金的存放與使用情況進行了審核，並出具了鑑證報告，認為復星醫藥的專項報告在所有重大方面均符合相關規定，真實反映了2023年度募集資金的存放與實際使用情況。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）於2024年3月26日發布了2023年度募集資金存放與實際使用情況的專項報告。報告顯示，復星醫藥於2022年7月非公開發行股票，募集資金總額達人民幣448.38億元，扣除發行費用後淨額為人民幣445.62億元。截至2023年12月31日，已累計使用募集資金人民幣367.14億元。報告期內實際使用了人民幣64.42億元，募集資金餘額為人民幣78.48億元。此外，復星醫藥調整了部分募集資金的投資項目，以加快創新藥物研發進度，並提高資金使用效率。安永華明會計師事務所對募集資金的存放與使用情況進行了審核，並出具了鑑證報告，認為復星醫藥的專項報告在所有重大方面均符合相關規定，真實反映了2023年度募集資金的存放與實際使用情況。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ISSUED A SPECIAL REPORT ON THE STORAGE AND ACTUAL USE OF FUNDS FOR THE YEAR 2023 ON MARCH 26, 2024. The report showed that Fustar Pharmaceuticals issued non-public shares in July 2022 with a total raised amount of RMB448.38 billion, net post-issuance costs of RMB445.62 billion. As of 31 December 2023, RMB367.14 billion has been used to raise funds cumulatively. RMB64.42 billion was actually used during the reporting period, and the fundraising balance was RMB78.48 billion. IN ADDITION, FUSTAR PHARMACEUTICALS HAS ADJUSTED SOME OF ITS FUND-RAISING INVESTMENTS TO ACCELERATE THE PROGRESS OF INNOVATIVE DRUG R&D AND IMPROVE THE EFFICIENCY OF ITS USE OF FUNDS. EY's accounting firm audited the storage and use of the funds raised and produced an audit report that concluded that Resusant Pharmaceuticals' specific reports met the relevant requirements in all important respects and truly reflected the storage and actual use of the funds raised in 2023.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ISSUED A SPECIAL REPORT ON THE STORAGE AND ACTUAL USE OF FUNDS FOR THE YEAR 2023 ON MARCH 26, 2024. The report showed that Fustar Pharmaceuticals issued non-public shares in July 2022 with a total raised amount of RMB448.38 billion, net post-issuance costs of RMB445.62 billion. As of 31 December 2023, RMB367.14 billion has been used to raise funds cumulatively. RMB64.42 billion was actually used during the reporting period, and the fundraising balance was RMB78.48 billion. IN ADDITION, FUSTAR PHARMACEUTICALS HAS ADJUSTED SOME OF ITS FUND-RAISING INVESTMENTS TO ACCELERATE THE PROGRESS OF INNOVATIVE DRUG R&D AND IMPROVE THE EFFICIENCY OF ITS USE OF FUNDS. EY's accounting firm audited the storage and use of the funds raised and produced an audit report that concluded that Resusant Pharmaceuticals' specific reports met the relevant requirements in all important respects and truly reflected the storage and actual use of the funds raised in 2023.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more